• 1 ml Viscum album Fraxini ex herba recente col. D30

• water for injections

Active Benign tumor, malignant tumor, cancer, ABNOBAVISCUM Fraxini D 30 ampoules ingredient:

Each ampoule contains 1 ml Viscum album Fraxini ex herba recente col. D30.

What is abnoba VISCUM and what is it used for?
abnobaVISCUM is an anthroposophic medicinal product for the extended treatment of tumor diseases.

Areas of Benign tumor, malignant tumor, cancer, ABNOBAVISCUM Fraxini D 30 ampoules application:

According to anthroposophical knowledge of man and nature, abnoba-VISCUM is used to stimulate the formative and integrative forces in adults to dissolve and reintegrate independent growth processes, e.g

• in malignant tumor diseases, also with accompanying disorders of the blood-forming organs
• in benign tumor diseases
• to prevent recurrence (recurrence prophylaxis) after tumor surgery
• in the early stages of certain cancers (defined precancerous lesions).
   

How is abnobaViSCUM to be used?

Type of Benign tumor, malignant tumor, cancer, ABNOBAVISCUM Fraxini D 30 ampoules application: If
possible, the subcutaneous injection should be carried out in the vicinity of the tumor or metastases, otherwise in constantly changing parts of the body (different parts in the abdominal area, possibly thigh or upper arm).

Do not inject into inflamed skin areas or radiation fields. Strictly subcutaneous injection technique should be used.

As a precaution, it is recommended not to draw up abnobaVISCUM with other medicines in one syringe.

After cleaning the puncture site (e.g. by rubbing with 70% alcohol), fold the skin and insert the injection needle at an angle. Slightly withdraw the syringe plunger. If blood appears, a blood vessel has been hit.

In this case, repeat the injection at a different site. If no blood appears, inject slowly, then withdraw the needle and briefly press the puncture site with a swab.

In any case, it is recommended to learn the injection technique from a person experienced in it.

Ampoules should be injected immediately after opening. Opened ampoules must not be used for a later injection.

Only the potency levels D 10, D 20 and D 30:
For the potency levels D 10, D 20 and D 30, the required dose can be mixed into an infusion solution (physiological saline solution or 5% glucose solution) and slowly infused intravenously in special cases. The infusion time should be at least 90 minutes for 250 ml.

Dosage Benign tumor, malignant tumor, cancer, ABNOBAVISCUM Fraxini D 30 ampoules and frequency of use
depend on the respective physical condition and are determined individually by your doctor.

Dosage and frequency of use:
Initiation phase:
Unless otherwise stated, the dosage is always 1 ml of the injection solution of the specified strength or potency level. You should start treatment with the 0.02 mg strength three times a week (for the 0.02 mg, 0.2 mg, 2 mg, 20 mg and potency level D 6 strengths) and then cautiously continue with the next higher doses until until you reach the optimal dose.

The dosage is always individual according to the doctor's instructions and depends on your reaction situation.

The potency levels D 10 – D 30 are to be used according to the individual indication.

The optimal concentration or dose must be determined individually. According to the current state of knowledge, the following reactions, which can occur individually or in combination, must be observed:

a) Change in subjective well-being:
improvement in general well-being (increase in appetite and weight, normalization of sleep, sensitivity to warmth and performance) and mental well-being (brightening of mood, increase in courage and initiative) as well as alleviation of pain show you that you dose in the effective range.

Any fatigue, shivering, general feeling of illness, headaches and brief dizziness that may occur on the day of the injection are not signs of intolerance, but indicate an effective dosage that may already be too high.

If these symptoms have not disappeared by the following day or are above a tolerable level, the strength or dose should be reduced.

b) Temperature response:
A temperature response in the form of an above-average increase in body temperature a few hours after injection, in the form of a restoration of the physiological morning/evening difference of at least 0.5°C, or an increase in the mean temperature level during treatment.

In the case of tumor fever, on the other hand, low concentrations are used to normalize and rhythmize the core temperature.

c) Immunological reaction:
Your doctor can determine a positive reaction of your immune system through laboratory tests of your blood. This can be demonstrated, for example, by an increase in certain white blood cells (lymphocytes and eosinophils) in the blood and by an improvement in the cellular immune status in the recall antigen test or when determining the lymphocyte subpopulations.

d) Local inflammatory reaction:
A local reaction occurs at the injection site.

This should not be larger than 5 cm in diameter.

Maintenance phase:
Unless otherwise prescribed:
The individual dose can be as low as 0.02 mg. Otherwise, gradually increase the concentration to strengths of 0.2 mg, 2 mg and 20 mg, each with 2-3 injections per week.

Since violent reactions can occur when changing from one strength to the next, only half an ampoule of the next higher concentration should be injected at first. If too strong reactions occur even with the strength of 0.02 mg, you should switch to the potency level D6.

If the reactions are too strong here too, you should only use a third of the ampoule, switch to D10 or to abnobaVISCUM from another host tree.

In the cases mentioned above, the use of 0.5 ml or 0.3 ml abnobaVISCUM using a graduated 1 ml syringe is recommended.

During radiotherapy, chemotherapy or hormone therapy or after an operation, your individual reaction situation may change, making it necessary to adjust the dose.

The treatment is continued with the optimal individual concentration or dose determined in this way.

To avoid habituation effects, rhythmic application is recommended in the form of:
alternation with lower concentrations or doses in the form of increasing and possibly also decreasing dosages or repeating the rhythm of the injection intervals.

The dosage should be reviewed at intervals of 3-6 months based on patient response and tumor behavior.

Dosage in the case of impaired renal function:
There is insufficient data for specific dosage recommendations in the case of impaired renal function. General experience has so far shown no need for dose adjustment.

Duration of use:
In principle, the duration of treatment is not limited. It is determined by your doctor and depends on the respective risk of a tumor recurrence (recurrence of a similar tumor after previous treatment) and on your individual condition or findings. It should be several years, with breaks of increasing length usually being taken.

Application errors:
If you have used a larger amount of abnobaVISCUM than you should, reactions such as those described under side effects can occur.

The next injection should then only be given after these symptoms have subsided and at a reduced dosage.

If you have forgotten to use abnobaVISCUM, follow your normal therapy plan for the further injections.

If you stop using abnobaVISCUM, you have to start again with the low starting dose when you start the therapy again.

What abnobaVISCUM contains:
The active substance is 1 ml Viscum album Fraxini ex herba recente col. dil. D 30 (HAB, v. 32).

Other ingredients: none